CU20170162A7 - Derivados de fenil-tieno(2,3-d)pirimidina-hidroxiácido útiles en el tratamiento del cáncer y enfermedades autoinmunes, método de preparación de los mismos y composiciones farmacéuticas que los contienen - Google Patents

Derivados de fenil-tieno(2,3-d)pirimidina-hidroxiácido útiles en el tratamiento del cáncer y enfermedades autoinmunes, método de preparación de los mismos y composiciones farmacéuticas que los contienen

Info

Publication number
CU20170162A7
CU20170162A7 CUP2017000162A CU20170162A CU20170162A7 CU 20170162 A7 CU20170162 A7 CU 20170162A7 CU P2017000162 A CUP2017000162 A CU P2017000162A CU 20170162 A CU20170162 A CU 20170162A CU 20170162 A7 CU20170162 A7 CU 20170162A7
Authority
CU
Cuba
Prior art keywords
cancer
phenyl
useful
preparation
treatment
Prior art date
Application number
CUP2017000162A
Other languages
English (en)
Spanish (es)
Inventor
Balázs Bálint
Maïa Chanrion
James Edward Paul Davidson
Olivier Geneste
András Kotschy
James Brooke Murray
Attila Paczal
Ágnes Proszenyák
Szabolcs Sipos
Zoltán Szlávik
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Publication of CU20170162A7 publication Critical patent/CU20170162A7/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
CUP2017000162A 2015-06-23 2016-06-22 Derivados de fenil-tieno(2,3-d)pirimidina-hidroxiácido útiles en el tratamiento del cáncer y enfermedades autoinmunes, método de preparación de los mismos y composiciones farmacéuticas que los contienen CU20170162A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1555753A FR3037958B1 (fr) 2015-06-23 2015-06-23 Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/EP2016/064417 WO2016207216A1 (fr) 2015-06-23 2016-06-22 Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant

Publications (1)

Publication Number Publication Date
CU20170162A7 true CU20170162A7 (es) 2018-06-05

Family

ID=54260902

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2017000162A CU20170162A7 (es) 2015-06-23 2016-06-22 Derivados de fenil-tieno(2,3-d)pirimidina-hidroxiácido útiles en el tratamiento del cáncer y enfermedades autoinmunes, método de preparación de los mismos y composiciones farmacéuticas que los contienen

Country Status (45)

Country Link
US (1) US10322131B2 (fr)
EP (1) EP3313849B8 (fr)
JP (1) JP6773695B2 (fr)
KR (1) KR102620976B1 (fr)
CN (1) CN107922432B (fr)
AR (1) AR105104A1 (fr)
AU (1) AU2016282827B2 (fr)
BR (1) BR112017027831A2 (fr)
CA (1) CA2990083C (fr)
CL (1) CL2017003316A1 (fr)
CO (1) CO2017012845A2 (fr)
CU (1) CU20170162A7 (fr)
DK (1) DK3313849T3 (fr)
DO (1) DOP2017000304A (fr)
EA (1) EA036503B1 (fr)
EC (1) ECSP17082825A (fr)
ES (1) ES2944942T3 (fr)
FI (1) FI3313849T3 (fr)
FR (1) FR3037958B1 (fr)
GE (1) GEP20207076B (fr)
HK (2) HK1250233A1 (fr)
HR (1) HRP20230472T1 (fr)
HU (1) HUE061758T2 (fr)
IL (1) IL256320A (fr)
JO (1) JO3807B1 (fr)
LT (1) LT3313849T (fr)
MA (1) MA42231B1 (fr)
MD (1) MD3313849T2 (fr)
MX (1) MX2017017008A (fr)
MY (1) MY190243A (fr)
PE (1) PE20180949A1 (fr)
PH (1) PH12017502314A1 (fr)
PL (1) PL3313849T3 (fr)
PT (1) PT3313849T (fr)
RS (1) RS64131B1 (fr)
RU (1) RU2745430C9 (fr)
SA (1) SA517390586B1 (fr)
SI (1) SI3313849T1 (fr)
SV (1) SV2017005590A (fr)
TN (1) TN2017000529A1 (fr)
TW (2) TW202108590A (fr)
UA (1) UA124759C2 (fr)
UY (1) UY36735A (fr)
WO (1) WO2016207216A1 (fr)
ZA (1) ZA201708626B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2017300738A1 (en) 2016-07-22 2019-02-07 Les Laboratoires Servier Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
EP3567043B1 (fr) * 2017-01-05 2023-12-06 Henan Genuine Biotech Co., Ltd. Dérivés du acide propanoïque 2-[[5-[(4-hydroxy-3-chloro-2-méthyl)-phényl]-thiéno[2,3-d]pyrimidin-4-yl]oxy]-3-(2-méthoxybenzene) en tant qu'inhibiteurs mcl-1 et bcl-2 pour le traitement du cancer
CA3049095C (fr) * 2017-01-06 2022-01-25 Les Laboratoires Servier Combinaison d'un inhibiteur de mcl-1 et d'un compose de taxane, ses utilisations et compositions pharmaceutiques la comprenant
UY37560A (es) * 2017-01-06 2018-07-31 Servier Lab Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
TWI753178B (zh) * 2017-06-22 2022-01-21 法商施維雅藥廠 Mcl-1抑制劑與血液癌症標準療法之組合，其用途及醫藥組合物
UA126586C2 (uk) 2017-08-15 2022-11-02 Еббві Інк. Макроциклічні інгібітори mcl-1 та способи їх застосування
EP3668503A4 (fr) * 2017-08-15 2021-04-07 AbbVie Inc. Inhibiteurs de mcl-1 macrocyclique et procédés d'utilisation
WO2019101144A1 (fr) * 2017-11-23 2019-05-31 北京赛林泰医药技术有限公司 Inhibiteur sélectif de mcl-1, préparation et utilisation associées
CN108424417B (zh) * 2017-12-21 2019-09-20 河南真实生物科技有限公司 噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用
AR116635A1 (es) 2018-10-15 2021-05-26 Servier Lab Proceso para la síntesis de derivados de piperazinil-etoxi-bromofenilo y su aplicación en la producción de compuestos que los contienen
EP3880207B1 (fr) 2018-11-14 2024-03-27 Les Laboratoires Servier Combinaison d'un inhibiteur de mcl-1 et de midostaurine, utilisations et compositions pharmaceutiques associées
JP2022533400A (ja) * 2019-05-20 2022-07-22 ノバルティス アーゲー Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法
TW202114682A (zh) 2019-06-17 2021-04-16 法商施維雅藥廠 Mcl-1抑制劑與乳癌標準療法之組合，其用途及醫藥組合物
CN113024577B (zh) * 2019-12-09 2023-06-30 首药控股(北京)股份有限公司 一种抗凋亡蛋白选择性抑制剂的制备方法
CN117136076A (zh) 2020-11-24 2023-11-28 诺华股份有限公司 Mcl-1抑制剂抗体药物缀合物和使用方法
CA3222752A1 (fr) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Inhibiteurs de mcl-1 en combinaison avec des conjugues anti-corps-medicament
AU2022291381A1 (en) 2021-06-11 2023-11-30 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
WO2023225359A1 (fr) 2022-05-20 2023-11-23 Novartis Ag Conjugués anticorps-médicament de composés anti-cancéreux et procédés d'utilisation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070213305A1 (en) * 2005-11-02 2007-09-13 Cytovia, Inc. N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
AU2008240188A1 (en) * 2007-04-13 2008-10-23 Supergen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
CN102464667B (zh) * 2010-11-03 2014-06-04 中国科学院上海药物研究所 一类五元杂环并嘧啶类化合物及其制备方法和用途
AR090037A1 (es) * 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
FR2986002B1 (fr) * 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) * 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
HRP20230472T1 (hr) 2023-07-21
US10322131B2 (en) 2019-06-18
US20180185369A1 (en) 2018-07-05
UY36735A (es) 2016-12-30
CN107922432B (zh) 2021-05-04
CN107922432A (zh) 2018-04-17
GEP20207076B (en) 2020-03-10
SA517390586B1 (ar) 2022-02-20
AU2016282827A1 (en) 2018-01-18
CL2017003316A1 (es) 2018-04-27
MA42231B1 (fr) 2023-04-28
HK1254477A1 (zh) 2019-07-19
PH12017502314B1 (en) 2018-06-25
PH12017502314A1 (en) 2018-06-25
DK3313849T3 (da) 2023-05-30
AR105104A1 (es) 2017-09-06
RU2745430C1 (ru) 2021-03-25
PE20180949A1 (es) 2018-06-11
CO2017012845A2 (es) 2018-03-28
SV2017005590A (es) 2018-06-01
TW201712019A (zh) 2017-04-01
PL3313849T3 (pl) 2023-07-10
FI3313849T3 (fi) 2023-05-11
HK1250233A1 (zh) 2018-12-07
MD3313849T2 (ro) 2023-07-31
TN2017000529A1 (en) 2019-04-12
EP3313849B1 (fr) 2023-02-22
ECSP17082825A (es) 2018-02-28
RU2745430C9 (ru) 2021-06-28
RS64131B1 (sr) 2023-05-31
FR3037958B1 (fr) 2019-01-25
ES2944942T3 (es) 2023-06-27
IL256320A (en) 2018-02-28
JP2018527296A (ja) 2018-09-20
CA2990083C (fr) 2021-05-25
KR102620976B1 (ko) 2024-01-05
BR112017027831A2 (pt) 2018-09-04
CA2990083A1 (fr) 2016-12-29
TW202108590A (zh) 2021-03-01
SI3313849T1 (sl) 2023-07-31
LT3313849T (lt) 2023-05-10
UA124759C2 (uk) 2021-11-17
MX2017017008A (es) 2018-08-15
HUE061758T2 (hu) 2023-08-28
MY190243A (en) 2022-04-07
PT3313849T (pt) 2023-04-18
TWI715593B (zh) 2021-01-11
MA42231A (fr) 2018-05-02
FR3037958A1 (fr) 2016-12-30
EA201890124A1 (ru) 2018-05-31
AU2016282827B2 (en) 2020-07-09
JO3807B1 (ar) 2021-01-31
ZA201708626B (en) 2022-06-29
WO2016207216A1 (fr) 2016-12-29
DOP2017000304A (es) 2018-02-28
JP6773695B2 (ja) 2020-10-21
KR20180015263A (ko) 2018-02-12
EA036503B1 (ru) 2020-11-17
EP3313849B8 (fr) 2023-05-10
EP3313849A1 (fr) 2018-05-02

Similar Documents

Publication Publication Date Title
CU20170162A7 (es) Derivados de fenil-tieno(2,3-d)pirimidina-hidroxiácido útiles en el tratamiento del cáncer y enfermedades autoinmunes, método de preparación de los mismos y composiciones farmacéuticas que los contienen
CU20170160A7 (es) Derivadosde fenil-tieno(2,3-d)pirimidina- hidroxi-ésteres, un proceso para su preparación y composiciones farmacéuticas que lo contienen
ECSP17083003A (es) Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen
CR20170590A (es) Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
PE20151064A1 (es) Nuevos derivados tienopirimidina, un proceso para su preparacion y composiciones farmaceuticas que los contienen
UY37007A (es) Compuestos derivados de purinas, estimuladores de genes de interferón
DOP2015000157A (es) Lactamas fusionadas de arilo y heteroarilo
CR20180232A (es) Macrociclos peptídicos contra acinetobacter baumannii
NI201400107A (es) Compuestos de heterociclilo como inhibidores de mek
UY35898A (es) ?compuestos inhibidores de syk y composiciones que los comprenden?.
CU20140048A7 (es) Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos
BR112018011929A2 (pt) composto, composição farmacêutica, métodos para tratamento da infecção viral da hepatite c, de carcinoma basocelular, de ceratose actínica, da infecção viral de papiloma genital e da infecção viral de hepatite c, processo para preparação de um composto, e, uso de um composto
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
ECSP17069696A (es) Compuestos novedosos
CO2017003004A2 (es) Nuevas triazolo[4,5-d]pirimidinas
CU20170007A7 (es) Compuestos de imidazopiridazina
CY1120602T1 (el) [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων
DOP2018000083A (es) NUEVOS DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
UY36228A (es) Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen
CL2018000856A1 (es) Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida.
DOP2016000293A (es) Derivados de diheterociclo enlazado a cicloalquilo
EA201791396A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
EA201791397A1 (ru) СВЯЗАННЫЕ С ГЕТЕРОЦИКЛИЛАМИ ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
CR20150641U (es) Composiciones farmacéuticas
ECSP17046657A (es) Síntesis total de trioxacarcina dc-45-a2 y preparación de análogos de trioxacarcina